TRENTON, N.J. — The maker of EpiPen emergency allergy injectors, under a microscope for repeatedly jacking up the price of the life-saving device, revealed Wednesday that it’s a target of two price-related probes by federal agencies and has had its premises searched.

The news, disclosed in a filing with the Securities and Exchange Commission, came after Mylan Inc. reported that it swung to a third-quarter loss, mainly due to a big settlement for overcharging the federal government for the product.

Mylan’s results missed Wall Street expectations, and the company stuck with the reduced 2016 profit forecast it issued last month when it announced that $465 million settlement.

In the SEC filing late Wednesday, Mylan disclosed that on Oct. 7, “Mylan received a document request from the Division of Enforcement at the SEC seeking communications” with the Centers for Medicare and Medicaid and documents concerning Mylan products sold to the Medicaid Drug Rebate Program.”

Mylan, which is technically based in England but operates out of its Pittsburgh-area headquarters, also disclosed in the filing that on Sept. 8, the Department of Justice subpoenaed a company subsidiary, a senior executive and other employees about alleged price fixing and also executed multiple search warrants related to its probe.

Mylan said that Justice is seeking “additional information relating to the marketing, pricing and sale of” four generic medicines — cidofovir, glipizide-metformin, propranolol and verapamil — “and any communications with competitors about such products.”